曲美他嗪对缺血性心肌病心力衰竭疗效观察  

Efficacy observation of Trimetazidine in the treatment of ischemic cardiomyopathy complicated with heart failure

作　　者：郭园园[1] GUO Yuan-yuan(Department of Emergency,Weifang Hospital of Traditional Chinese Medicine,Weifang 261000,China)

机构地区：[1]潍坊市中医院急诊科,261000

出　　处：《中国实用医药》2018年第31期6-7,共2页China Practical Medicine

摘　　要：目的探讨曲美他嗪对缺血性心肌病心力衰竭的临床治疗以及稳定心率并减轻心肌损伤的效果。方法 78例缺血性心肌病心力衰竭患者作为研究对象,按照随机数字表法分为观察组与对照组,各39例。对照组应用常规疗法,观察组在对照组基础上加用曲美他嗪,比较两组患者的疗效、心率变异性指标。结果观察组总有效率为94.87%显著高于对照组的79.49%,差异有统计学意义(P<0.05)。治疗后,观察组患者全部窦性RR间期标准差(SDNN)、每5分钟窦性RR间期平均值的标准差(SDANN)、相邻RR间期差值的均方差(RMSSD)以及相邻NN之差>50 ms的个数占总窦性心博的百分比(PNN50)分别为(125.46±17.62)ms、(113.74±14.57)ms、(46.74±10.63)ms、(20.21±5.76)%,均优于对照组的(106.82±13.92)ms、(92.45±13.16)ms、(37.21±9.76)ms、(12.36±4.23)%,差异有统计学意义(P<0.05)。结论应用曲美他嗪治疗缺血性心肌病心力衰竭患者,可显著提高临床治疗效果。Objective To explore the effect of Trimetazidine on the clinical treatment of this disease, stabilizing heart rate and reducing myocardial injury. Methods A total of 78 ischemic cardiomyopathy patients complicated with heart failure were divided into observation group and control group according to the random number table method, 39 cases in each group. The control group was treated with conventional therapy, the observation group was treated with Timetazidine on the basis of the control group. The curative effect and heart rate variability between the two groups were compared. Results The total effective rate of the observation group was 94.87%, which was significantly higher than 79.49% of the control group, the difference was statistically significant（P〈0.05）. After treatment, the standard deviation of all normal to normal RR intervals（SDNN）, the standard deviation of the means of NN intervals in all 5-minute segments of the entire recording（SDANN）, root mean square successive difference between normal adjacent RR intervals（RMSSD） and the percentage of differences between adjacent normal RR intervals exceeding 50 milliseconds（PNN50） in the observation group were（125.46±17.62） ms,（113.74±14.57） ms,（46.74±10.63） ms and（20.21±5.76）% respectively, which were（106.82±13.92） ms,（92.45±13.16） ms,（37.21±9.76） ms and（12.36±4.23）% in the control group, the differences were statistically significant（P0.05）. Conclusion The application of Trimetazidine in the treatment of ischemic cardiomyopathy patients complicated with heart failure can significantly improve the clinical therapeutic effect.

关 键 词：曲美他嗪 心力衰竭 缺血性心肌病 疗效 

分 类 号：R541.6[医药卫生—心血管疾病]